Exact Sciences (EXK) Stock Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EXK Analyst Ratings

Hold

0 Buy

15 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Exact

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EXK Stock 12 Month Forecast

Average Price Target

€88.66

▲(2.07% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Exact Sciences in the last 3 months. The average price target is €88.66 with a high forecast of €88.66 and a low forecast of €88.66. The average price target represents a 2.07% change from the last price of €86.86.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"€38","89":"€89","50.75":"€50.8","63.5":"€63.5","76.25":"€76.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":88.65779685,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€88.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.65779685,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€88.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":88.65779685,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€88.66</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,50.75,63.5,76.25,89],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.23,85.49367668076924,85.75735336153846,86.0210300423077,86.28470672307692,86.54838340384616,86.81206008461538,87.07573676538462,87.33941344615384,87.60309012692308,87.8667668076923,88.13044348846154,88.39412016923076,{"y":88.65779685,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.23,85.49367668076924,85.75735336153846,86.0210300423077,86.28470672307692,86.54838340384616,86.81206008461538,87.07573676538462,87.33941344615384,87.60309012692308,87.8667668076923,88.13044348846154,88.39412016923076,{"y":88.65779685,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.23,85.49367668076924,85.75735336153846,86.0210300423077,86.28470672307692,86.54838340384616,86.81206008461538,87.07573676538462,87.33941344615384,87.60309012692308,87.8667668076923,88.13044348846154,88.39412016923076,{"y":88.65779685,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.12,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.025,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.805,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.205,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.88,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.07,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.23,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€88.66

Average Price Target€88.66

Lowest Price Target€88.66

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kyle Mikson CFA

Canaccord Genuity

€88.66

Hold

2.07%

Upside

Reiterated

02/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Exact Sciences (NASDAQ: EXAS) and Glaukos (NYSE: GKOS)

Subbu Nambi

Guggenheim

Hold

―

Reiterated

02/16/26

Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS), HeartFlow, Inc. (NASDAQ: HTFL) and Pelthos Therapeutics (NYSE MKT: PTHS)

Bradley Bowers

Mizuho Securities

€88.66

Hold

2.07%

Upside

Downgraded

01/20/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (NYSE: A), DENTSPLY SIRONA (NASDAQ: XRAY) and Exact Sciences (NASDAQ: EXAS)

Daniel Brennan

TD Cowen

€88.66

Hold

2.07%

Upside

Reiterated

01/07/26

Patrick B Donnelly

Citi

€88.66→

Hold

―

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX) and Exact Sciences (NASDAQ: EXAS)

Vijay Kumar

Evercore ISI

€88.66

Hold

2.07%

Upside

Downgraded

01/05/26

Exact Sciences downgraded to In Line from Outperform at Evercore ISIExact Sciences downgraded to In Line from Outperform at Evercore ISI

Daniel Arias

Stifel Nicolaus

€67.55→€88.66

Hold

2.07%

Upside

Downgraded

11/28/25

Exact Sciences downgraded to Hold from Buy at StifelExact Sciences downgraded to Hold from Buy at Stifel

William Bonello

Craig-Hallum

€71.77→€88.66

Hold

2.07%

Upside

Downgraded

11/24/25

Craig-Hallum downgrades Exact Sciences (EXAS) to a Hold

Tycho Peterson

Jefferies

€88.66

Hold

2.07%

Upside

Downgraded

11/24/25

Exact Sciences Downgraded to Hold Amid ABT Acquisition and Market Uncertainties

David Westenberg

Piper Sandler

€67.55→€88.66

Hold

2.07%

Upside

Downgraded

11/24/25

Exact Sciences downgraded to Neutral from Overweight at Piper SandlerExact Sciences downgraded to Neutral from Overweight at Piper Sandler

Bruce Jackson

Benchmark Co.

Hold

―

Downgraded

11/24/25

Exact Sciences downgraded to Hold from Buy at BenchmarkExact Sciences downgraded to Hold from Buy at Benchmark

Brandon Couillard

Wells Fargo

€71.77→€88.66

Hold

2.07%

Upside

Downgraded

11/21/25

Exact Sciences downgraded to Equal Weight from Overweight at Wells FargoExact Sciences downgraded to Equal Weight from Overweight at Wells Fargo

Jack Meehan

Nephron

€88.66

Hold

2.07%

Upside

Downgraded

11/21/25

Exact Sciences downgraded to Hold from Buy at Nephron ResearchExact Sciences downgraded to Hold from Buy at Nephron Research

Andrew Brackmann

William Blair

Hold

―

Downgraded

11/21/25

Analysts Are Bullish on These Healthcare Stocks: Nano-X Imaging (NNOX), Exact Sciences (EXAS)

Luke Sergott

Barclays

€65.02→€88.66

Hold

2.07%

Upside

Reiterated

11/21/25

Barclays downgrades Exact Sciences (EXAS) to a Hold

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kyle Mikson CFA

Canaccord Genuity

€88.66

Hold

2.07%

Upside

Reiterated

02/17/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Beta Bionics, Inc. (NASDAQ: BBNX), Exact Sciences (NASDAQ: EXAS) and Glaukos (NYSE: GKOS)

Subbu Nambi

Guggenheim

Hold

―

Reiterated

02/16/26

Analysts Offer Insights on Healthcare Companies: Exact Sciences (NASDAQ: EXAS), HeartFlow, Inc. (NASDAQ: HTFL) and Pelthos Therapeutics (NYSE MKT: PTHS)

Bradley Bowers

Mizuho Securities

€88.66

Hold

2.07%

Upside

Downgraded

01/20/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Agilent (NYSE: A), DENTSPLY SIRONA (NASDAQ: XRAY) and Exact Sciences (NASDAQ: EXAS)

Daniel Brennan

TD Cowen

€88.66

Hold

2.07%

Upside

Reiterated

01/07/26

Patrick B Donnelly

Citi

€88.66→

Hold

―

Reiterated

01/05/26

Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (NASDAQ: CRNX) and Exact Sciences (NASDAQ: EXAS)

Vijay Kumar

Evercore ISI

€88.66

Hold

2.07%

Upside

Downgraded

01/05/26

Exact Sciences downgraded to In Line from Outperform at Evercore ISIExact Sciences downgraded to In Line from Outperform at Evercore ISI

Daniel Arias

Stifel Nicolaus

€67.55→€88.66

Hold

2.07%

Upside

Downgraded

11/28/25

Exact Sciences downgraded to Hold from Buy at StifelExact Sciences downgraded to Hold from Buy at Stifel

William Bonello

Craig-Hallum

€71.77→€88.66

Hold

2.07%

Upside

Downgraded

11/24/25

Craig-Hallum downgrades Exact Sciences (EXAS) to a Hold

Tycho Peterson

Jefferies

€88.66

Hold

2.07%

Upside

Downgraded

11/24/25

Exact Sciences Downgraded to Hold Amid ABT Acquisition and Market Uncertainties

David Westenberg

Piper Sandler

€67.55→€88.66

Hold

2.07%

Upside

Downgraded

11/24/25

Exact Sciences downgraded to Neutral from Overweight at Piper SandlerExact Sciences downgraded to Neutral from Overweight at Piper Sandler

Bruce Jackson

Benchmark Co.

Hold

―

Downgraded

11/24/25

Exact Sciences downgraded to Hold from Buy at BenchmarkExact Sciences downgraded to Hold from Buy at Benchmark

Brandon Couillard

Wells Fargo

€71.77→€88.66

Hold

2.07%

Upside

Downgraded

11/21/25

Exact Sciences downgraded to Equal Weight from Overweight at Wells FargoExact Sciences downgraded to Equal Weight from Overweight at Wells Fargo

Jack Meehan

Nephron

€88.66

Hold

2.07%

Upside

Downgraded

11/21/25

Exact Sciences downgraded to Hold from Buy at Nephron ResearchExact Sciences downgraded to Hold from Buy at Nephron Research

Andrew Brackmann

William Blair

Hold

―

Downgraded

11/21/25

Analysts Are Bullish on These Healthcare Stocks: Nano-X Imaging (NNOX), Exact Sciences (EXAS)

Luke Sergott

Barclays

€65.02→€88.66

Hold

2.07%

Upside

Reiterated

11/21/25

Barclays downgrades Exact Sciences (EXAS) to a Hold

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exact Sciences

3 Months

xxx

Success Rate

4/6 ratings generated profit

Average Return

+9.93%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +9.93% per trade.

1 Year

Michael RyskinBank of America Securities

Success Rate

8/10 ratings generated profit

Average Return

+53.22%

a rating ―

Copying Michael Ryskin's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +53.22% per trade.

2 Years

xxx

Success Rate

10/10 ratings generated profit

Average Return

+93.55%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +93.55% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXK Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EXK has received 0 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. EXK average Analyst price target in the past 3 months is 88.66.

Each month's total comprises the sum of three months' worth of ratings.

EXK Financial Forecast

EXK Earnings Forecast

Next quarter’s earnings estimate for EXK is -€0.16 with a range of -€0.49 to €0.04. The previous quarter’s EPS was -€0.38. EXK beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year EXK has Performed in-line its overall industry.

EXK Sales Forecast

Next quarter’s sales forecast for EXK is €708.62M with a range of €658.86M to €736.02M. The previous quarter’s sales results were €747.06M. EXK beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year EXK has Performed in-line its overall industry.

EXK Stock Forecast FAQ

What is DE:EXK’s average 12-month price target, according to analysts?

Based on analyst ratings, Exact Sciences Corp.’s 12-month average price target is 88.66.

What is DE:EXK’s upside potential, based on the analysts’ average price target?

Exact Sciences Corp. has 2.07% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Exact Sciences Corp. a Buy, Sell or Hold?

Exact Sciences Corp. has a consensus rating of Hold, which is based on 0 buy ratings, 15 hold ratings and 0 sell ratings.

What is Exact Sciences Corp.’s share price target?

The average share price target for Exact Sciences Corp. is 88.66. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €88.66 ,and the lowest forecast is €88.66. The average share price target represents 2.07% Increase from the current price of €86.86.

What do analysts say about Exact Sciences Corp.?

Exact Sciences Corp.’s analyst rating consensus is a Hold. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Exact Sciences Corp.?

To buy shares of DE:EXK, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Exact Sciences (EXK) Stock Forecast & Price Target

EXK Analyst Ratings

EXK Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Exact Sciences

EXK Analyst Recommendation Trends

EXK Financial Forecast

EXK Earnings Forecast

EXK Sales Forecast

EXK Stock Forecast FAQ

Detailed List of Analyst Forecasts